{"id":6663,"date":"2025-05-05T12:48:40","date_gmt":"2025-05-05T09:48:40","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6663"},"modified":"2025-05-05T12:48:40","modified_gmt":"2025-05-05T09:48:40","slug":"new-look-stroke-aspiration-catheter","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/new-look-stroke-aspiration-catheter\/","title":{"rendered":"New-look stroke aspiration catheter!"},"content":{"rendered":"<p>New-look stroke aspiration catheter!<\/p>\n<p>Summary:<br \/>\n1. Company &amp; Device: Irish company Perfuze. The catheter is the Millipede 088 Superbore aspiration catheter.<br \/>\n2. Purpose: The device is designed to treat large vessel occlusion (LVO) strokes by removing clots in a way that minimizes vessel damage \u2014 by \u201cingesting\u201d the blood clot as opposed to carrying it through the patient\u2019s blood vessels. According to Perfuze, this limits the risk of vessel damage or other procedure-related complications.<br \/>\n3. Trial Details: The MARRS trial enrolled 180 adult patients across the U.S. and Europe.<br \/>\n4. Primary Outcomes: The study focuses on successful reperfusion and symptomatic intracerebral hemorrhage within 24 hours post-treatment.<br \/>\n5. Regulatory Status: While Millipede 088 already has FDA clearance, Perfuze aims to use MARRS data for expanded approval.<br \/>\n6. Leadership Quotes: CEO Wayne Allen and principal investigator Dr. Raul Nogueira both praised the dedication of the medical teams and the bravery of the patients.<\/p>\n<p><a href=\"https:\/\/www.perfuze.com\/\">https:\/\/www.perfuze.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>New-look stroke aspiration catheter! Summary: 1. Company &amp; Device: Irish company Perfuze. The catheter is the Millipede 088 Superbore aspiration catheter. 2. Purpose: The device is designed to treat large vessel occlusion (LVO) strokes by removing clots in a way that minimizes vessel damage \u2014 by \u201cingesting\u201d the blood clot as opposed to carrying it [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6663","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6663"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6663\/revisions"}],"predecessor-version":[{"id":6664,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6663\/revisions\/6664"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}